Main Content

6. Pharmaceuticals

Pharmaceutical reimbursement and pricing policies pursue two goals: costs should be kept low relative to benefits and R&D should be encouraged. A commonly-used policy strategy is the concept of value-based pricing: reimbursement of pharmaceuticals is regulated on the basis of their therapeutic value. There are also value-based pricing policies taking into account both therapeutic relevance and economic considerations.


  • Analytical approaches for economic evaluation of pharmaceuticals, 2013
    Table | 01.11.2014 | Details | Download
  • Assessment of added therapeutic value and implications, 2013
    Table | 01.11.2014 | Details | Download
  • Bodies in charge of assessment and decisions on reimbursement status and/or price of pharmaceuticals, 2013
    Table | 01.11.2014 | Details | Download
  • Choice of relevant comparator to assess added therapeutic benefit or incremental cost-effectiveness ratio of pharmaceuticals, 2013
    Table | 01.11.2014 | Details | Download
  • Main criteria used to inform reimbursement decisions for products subject to assessment, 2013
    Table | 01.11.2014 | Details | Download
  • Patient contributions to the costs of reimbursed pharmaceuticals, 2012
    Table | 01.11.2014 | Details | Download
  • Perspective adopted for economic evaluation and/or costs of pharmaceuticals, 2013
    Table | 01.11.2014 | Details | Download
  • Pharmaceutical Sector Regulation in OECD Countries
    Report | 14.08.2009 | Details | Download
  • Regulation of prices or reimbursement prices of medicines, 2013
    Table | 01.11.2014 | Details | Download
  • Total pharmaceutical sales, per capita in US-Dollar at exchange rate, 1980 - 2013
    Table | 01.09.2014 | Details | Download | Visual Story
  • “End-of-Life” Drug Policies in the UK, Australia and Germany
    Report | 01.11.2012 | Details | Download

Visual Story on total pharmaceutical sales

Access full Visual Story


Short URL: www.ifo.de/de/w/3pbuoEuEb